Replimune shared on LinkedIn:
“Today, we announced that the FDA approval of our oncolytic immunotherapy.
Thank you to the patients, families, and clinicians who participated in our clinical trials as well as the many others including leading melanoma experts as well as advocacy groups who have supported our work over the past year.
Today would not be possible without you.”
Other articles about Replimune on OncoDaily.